Table 3.

Ongoing or recruiting studies in paediatric patients with inflammatory rheumatic diseases (July 2020)

Drug class	Drug	Study	Sponsor	Population	Region	Study duration	Primary outcome/endpoint
CD 80/86 inhibitor	abatacept	Limit-JIA, NCT03841357	Duke University	OJIA	United States	10/2019–12/2022	Joint count, active anterior uveitis
IL-23 inhibitor	guselkumab	aPROTOSTAR, NCT03451851	Janssen	Paediatric psoriasis	global	7/2018–6/2025	PASI75, PGA ≤1
	risankizumab	bM19–977, NCT04435600	Abbvie	Paediatric psoriasis	United States	7/2020–06/2025	PASI75; PGA ≤ 1
	tildrakizumab	TILD-19-12, NCT03997786	Sun Pharma Global FZE	Paediatric psoriasis	United States	1/2020–11/2023	PASI75, PGA ≤1
IL-17 inhibitor	brodalumab	cEMBRACE 1, NCT04305327	LEO Pharma	Paediatric psoriasis	global	9/2020–11/2023	PASI75
	secukinumab	dCAIN457F2304, NCT03031782	Novartis	PsA, ERA	global	5/2017–12/2020	Disease flare
		eCAIN457A2311, NCT03668613	Novartis	Paediatric psoriasis	global	8/2018–9/2023	PASI75, PGA ≤1
		fCAIN457A2310, NCT02471144	Novartis	Paediatric psoriasis	global	9/2015–7/2023	PASI75, PGA ≤1
TNF inhibitor	adalimumab	gADJUST, NCT03816397	UCSF	JIA-associated uveitis	United States	12/2019–12/2022	Treatment failure
	etanercept	STARS, EudraCT 2018–001931-27	IRCCS Istituto Giannina Gaslini	OJIA, PJIA	Italy	NA	Clinical inactive disease
	infliximab	KIDCARE, NCT03065244	UCSD	Kawasaki disease	United States	2/2017–9/2020	Fever
	certolizumab pegol	CIMcare, NCT04123795	UCB Biopharma	Paediatric psoriasis	North America	1/2020–4/2023	PASI75, PGA ≤1
JAK inhibitor	baricitinib	hJUVE-BRIGHT, NCT04088409	Eli Lilly	JIA-associated uveitis	Europe	10/2019–7/2022	Uveitis disease response
		iJUVE-BALM, NCT04088396	Eli Lilly	SJIA	global	2/2020–4/2023	Disease flare
		jJUVE-BASIS, NCT03773978	Eli Lilly	PJIA, extended OJIA, ERA, PsA	global	12/2018–8/2021	Disease flare
	tofacitinib	A3921165, NCT03000439	Pfizer	SJIA	global	5/2018–8/2023	Disease flare

Abbreviations: IL interleukin, TNF tumour necrosis factor, JAK Janus Kinase, ERA enthesitis-related juvenile idiopathic arthritis, JIA juvenile idiopathic arthritis, PsA, psoriatic juvenile idiopathic arthritis, OJIA oligoarticular juvenile idiopathic arthritis, PASI psoriasis area and severity index, PGA Physician global assessment, PJIA polyarticular juvenile idiopathic arthritis, SJIA systemic juvenile idiopathic arthritis, NA not applicable

^aAlso registered under EudraCT 2017–003053-42; ^bAlso registered under EudraCT 2019–004141-32, ^cAlso registered under EudraCT 2019–001868-30; ^dAlso registered under EudraCT 2016–003761-26; ^eAlso registered under EudraCT 2017–004515-39; ^fAlso registered under EudraCT 2014–005663-32; ^gAlso registered under EudraCT 2019–000412-29; ^hAlso registered under EudraCT 2019–00119-10; ⁱAlso registered under EudraCT 2017–004495-60; ^jAlso registered under EudraCT 2017–004518-24